Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Running, not enrolling · Phase 4 · Has a placebo group

Conditions studied: Hip Fractures

In brief

Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.

Key facts

Study ID

NCT03063892

Run by

Gregory M Georgiadis MD

People needed

200

Starts

2017-08-30

Expected to finish

2027-09-01

Last updated by the study team

2026-07-09

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Over the age of 60 years
• Hip fracture requiring surgical intervention
• Signs consent and agrees to participate

You may not qualify if…

• Under the age of 60
• Does not sign consent or refuses participation
• Known hypersensitivity to tranexamic acid
• Multiple acute fractures
• Creatinine clearance <30
• History of seizures
• Active hormone therapy
• History of coagulation abnormality
• History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE
• Myocardial infarction (MI) and/or stents within the past year
• History of intracranial hemorrhage
• Acquired defective color vision
• Patients admitted directly to nursing units or surgery without stay in the Emergency Center
• Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital

Where it is running

• ProMedica Toledo Hospital — Toledo, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.